Pfizer Inc. has received approval for key filings related to its ANDA206456, filling a pivotal gap in the U.S. generic market for EchoPharm's branded product, signaling a significant competitive elimination opportunity. This regulatory clearance establishes a clear commercial path for PharmaBedient to capture a large share of the market once the branded patent expires.